Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B

Journal of Clinical Oncology

Volumn 20, Issue 10, 2002, Pages 2429-2440

  Silverman, Lewis R ^a   Demakos, Erin P ^a   Peterson, Bercedis L ^a   Kornblith, Alice B ^a   Holland, Jimmie C ^a   Odchimar Reissig, Rosalie ^a   Stone, Richard M ^a   Nelson, Douglas ^a   Powell, Bayard L ^a   DeCastro, Carlos M ^a   Ellerton, John ^a   Larson, Richard A ^a   Schiffer, Charles A ^a   Holland, James F ^a  

^a University Medical Center of Southern Nevada   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW DEPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD CELL COUNT; BONE MARROW; CROSS-OVER STUDIES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, B-CELL; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037093195     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.04.117     Document Type: Article

References (88)

1. The Myelodysplastic Syndrome
2. Myelodysplastic syndromes: Analysis of 131 cases according to the FAB classification
3. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases
4. Myelodysplastic syndromes: A study of 101 cases according to the FAB classification
5. Myelodysplastic syndromes: A clinical and pathologic analysis of 109 cases
6. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome
7. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: A phase I-II trial
8. Treatment of anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin
9. Effects of recombinant human granulocyte colony-stimulating factor (CSF), human granulocyte macrophage-CSF, and gibbon interleukin-3 on hematopoiesis in human long-term bone marrow culture
10. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes: A phase I/II trial
11. Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): Results of a multi-center randomized controlled trial
12. Effectiveness of recombinant human erythropoietin therapy in myelodysplastic syndromes
13. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia
14. Efficacy of erythropoietin in the myelodysplastic syndrome: A meta-analysis of 205 patients from 17 studies
15. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia
16. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: A pilot study
17. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment
18. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia
19. Effect of chemotherapy for the dysmyelopoietic syndrome
20. Aggressive chemotherapy in adult primary myelodysplastic syndromes: A report of 29 cases
21. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes
22. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase III intergroup study
23. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome
24. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
25. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes
26. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome
27. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program
28. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
29. Cytotoxicity and mode of action of 5-azacytidine on 11210 leukemia
30. Azacitidine: 10 Years later
31. 5-Azacytidine, a new anti-cancer drug with effectiveness in acute myelogenous leukemia
32. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60)
33. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′deoxycytidine
34. Multiple new phenotypes induced in 10 T1/2 and 3T3 cell treated with azacytidine
35. Human leukemia K-562 cells: Induction of erythroid differentiation by 5-azacytidine
36. 5-Azacytidine selectively increases, gamma-globin synthesis in a patient with B+ thalassemia
37. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the g-d-beta-globin gene complex
38. Progress toward increasing fetal hemoglobin production in man: Experience with 5-azacytidine and hydroxyurea
39. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
40. Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921
41. Proposals for the classification of the acute leukemias: French-American-British (FAB) Co-operative Group
42. The French-American-British Cooperative Group: Proposals for the classification of the myelodysplastic syndromes
43. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
44. Holland J A model for quality-of-life research from the Cancer and Leukemia Group B: The telephone interview, conceptual approach, measurement, and theoretical framework
45. Nonparametric estimation from incomplete observations
46. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
47. Improved methodology forc analyzing local and distant recurrence
48. Pattern-mixture models for multivariate incomplete data
49. Mixture models for the joint distribution of repeated measures and event times
50. Impact of 5-azacytidine on the quality of life of myelodysplastic syndrome patients treated in a randomized phase III trial of the Cancer and Leukemia Group B (CALGB)
51. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study
52. International scoring system for evaluating prognosis in myelodysplastic syndromes
53. Group factors in worker productivity
54. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia
55. A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome
56. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome
57. Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome
58. All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome
59. 1,25-Dihydroxyvitamin D3: In vivo and in vitro effects of human preleukemic and leukemic cells
60. Responses of hemopoietic precursors to 13-cis retinoic acid and 1.25 dihydroxyvitamin D3 in the myelodysplastic syndromes
61. Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?
62. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes
63. Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside
64. Low-dose cytosine arabinoside in the treatment of acute nonlymphoblastic leukemia and myelodysplastic syndromes
65. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: A phase II clinical trial with a differentiation-inducing agent
66. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes
67. Multicenter randomized phase 11 trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia
68. Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C
69. Carboplatin plus cytarabine in the treatment of high-risk acute myeloblastic leukemia
70. Randomized phase Il study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
71. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemi
72. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders
73. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
74. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS)
75. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haematopoietic growth factors
76. Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand
77. Erythropoietin-induced activation of STAT 5 is impaired in the myelodysplastic syndrome
78. Analysis of the erythropoietin receptor gene in patients with myeloproliferative and myelodysplastic syndromes
79. Endogenous serum levels and surface receptor expression of GM-CSF and IL- 3 in patients with myelodysplastic syndromes
80. Azacitidine acts as biologic response modifier on hematopoietic cell response to cytokines
81. Modulation of the effects of hematopoietic cytokines on HL-60 acute promyelocytic leukemia cells by 5-azacytidine in vitro
82. Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW- 90
83. Methylation and gene control
84. DNA methylation and gene function
85. Hypomethylation of DNA during differentiation of Friend erythroleukemia cells
86. DNA methylatio and gene expression
87. Hypermethylation of the p 15INK4B gene in myelodysplastic syndromes
88. High-risk myelodysplastic syndromes and hypermethylation of the p 15Ink4B gene